Offloading treatment is linked to activation of proinflammatory cytokines and start of bone repair and remodeling in Charcot arthropathy patients

Journal of Foot and Ankle Research

Jean Cassuto⁴  Jan Göthlin⁵  Ylva Aurell⁵  Jesper Fowelin¹  Susanne Asteberg³  Martin Ålund³  Agnetha Folestad² 

[1] Diabetes Care Unit, Department of Medicine, Frölunda Specialist Hospital, Västra Frölunda, Göteborg, Sweden;Department of Orthopaedics, CapioLundby Hospital, Göteborg, Sweden;Department of Orthopaedics, Sahlgrenska University Hospital, Mölndal, Sweden;Orthopaedic Research Unit, Sahlgrenska University Hospital, Staben, Hus U1, 431 80 Mölndal, Sweden, Göteborg University, Göteborg, Sweden;Department of Radiology, Sahlgrenska University Hospital, Mölndal, Sweden

关键词: IL-1 receptor antibody;    TNF-alpha;    IL-1beta;    IL-8;    IL-6;    Proinflammatory cytokines;    Neuropathy;    Diabetes;    Offloading;    Fracture;    Bone healing;    Charcot foot;    Charcot arthropathy;   

Others  :  1235166
DOI  :  10.1186/s13047-015-0129-y

 received in 2015-09-09, accepted in 2015-11-30,  发布年份 2015

【 摘 要 】

Background

Proinflammatory cytokines are an integral part of the osteolytic activity of Charcot arthropathy but are also central to normal bone healing. As there are no previous longitudinal studies investigating their role during the recovery phase of Charcot, we set out to monitor systemic levels of proinflammatory cytokines from Charcot presentation until a clinically and radiographically documented chronic state has been reached.

Methods

Twenty-eight consecutive Charcot patients were monitored during 2 years by repeated foot radiographs, MRI and plasma levels of interleukin [IL]-6, IL-8, IL-1β, Tumor Necrosis Factor [TNF]-α, and IL-1 receptor antibody (IL-1RA). Charcot patients were treated with total contact cast (TCC) on the first day of inclusion. Neuropathic diabetic controls (n = 20) and Healthy subjects (n = 20) served as reference.

Results

Plasma IL-6, IL-8, IL-1β and TNF-α in the acute and chronic phase of Charcot were below or at the level of diabetic controls and healthy, whereas IL-1RA/IL-1β ratio was continuously higher in Charcot patients. IL-6, TNF-α and IL-1RA began to increase one week after offloading to reach a peak after 4 months before gradually receding.

Conclusions

A sustained increase of IL-6 and TNF-α starting shortly after offloading and paralleled by accelerated bone healing on radiographs, suggest that offloading, by activating the inflammatory stage, has a key role to play in the onset of coupled bone remodeling. High IL-1RA/IL-1β ratio in Charcot patients at presentation supports a counter-balancing anti-inflammatory role for IL-1RA in the acute phase whereas a high ratio after two years, possibly due to renewed weight-bearing on a deformed foot, signal need for continued anti-inflammatory activity and contradicts a “cold” biological state in the chronic phase.

【 授权许可】

   
2015 Folestad et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Mountziaris PM, Mikos AG. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev. 2008; 14:179-86.
• [2]Marzona L, Pavolini B. Play and players in bone fracture healing match. Clin Cases Miner Bone Metab. 2009; 6:159-62.
• [3]Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015; 11:45-54.
• [4]Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005; 366:2058-61.
• [5]Jeffcoate WJ. Charcot foot syndrome. Diabet Med. 2015; 32:760-70.
• [6]White ES, Mantovani AR. Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution. J Pathol. 2013; 229:141-4.
• [7]Robinson M, Fulcher M. Delayed healing of a navicular stress fracture, following limited weight-bearing activity. BMJ Case Rep. 2014;2014.
• [8]Wukich DK, Kline AJ. The management of ankle fractures in patients with diabetes. J Bone Joint Surg Am. 2008; 90:1570-8.
• [9]von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int J Surg. 2014.
• [10]Folestad A, Alund M, Asteberg S, Fowelin J, Aurell Y, Gothlin J et al.. Role of Wnt/beta-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Acta Orthop. 2015; 86:415-25.
• [11]Samuelsson P, Blohme G, Fowelin J, Eriksson JW. A new non-invasive method using pulse oximetry for the assessment of arterial toe pressure. Clin Physiol. 1996; 16:463-7.
• [12]Folestad A, Alund M, Asteberg S, Fowelin J, Aurell Y, Gothlin J et al.. IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study. Journal of foot and ankle research. 2015; 8:39. BioMed Central Full Text
• [13]Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle. 2013;4.
• [14]Sella EJ, Barrette C. Staging of Charcot neuroarthropathy along the medial column of the foot in the diabetic patient. J Foot Ankle Surg. 1999; 38:34-40.
• [15]Montagnani A, Gonnelli S. Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab. 2013; 15:784-91.
• [16]Oei L, Rivadeneira F, Zillikens MC, Oei EH. Diabetes, diabetic complications, and fracture risk. Current osteoporosis reports. 2015; 13:106-15.
• [17]Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res. 1988;210–6.
• [18]Wukich DK. Diabetes and its negative impact on outcomes in orthopaedic surgery. World journal of orthopedics. 2015; 6:331-9.
• [19]Saito M, Kida Y, Kato S, Marumo K. Diabetes, collagen, and bone quality. Current osteoporosis reports. 2014; 12:181-8.
• [20]Roszer T. Inflammation as death or life signal in diabetic fracture healing. Inflamm Res. 2011; 60:3-10.
• [21]Mabilleau G, Edmonds ME. Role of neuropathy on fracture healing in Charcot neuro-osteoarthropathy. J Musculoskelet Neuronal Interact. 2010; 10:84-91.
• [22]Kazamel M, Dyck PJ. Sensory manifestations of diabetic neuropathies: anatomical and clinical correlations. Prosthet Orthot Int. 2015; 39:7-16.
• [23]Schmidt-Bleek K, Kwee BJ, Mooney DJ, Duda GN. Boon and bane of inflammation in bone tissue regeneration and its link with Angiogenesis. Tissue Eng Part B Rev. 2015;21(4):354-64.
• [24]Komatsu DE, Warden SJ. The control of fracture healing and its therapeutic targeting: improving upon nature. J Cell Biochem. 2010; 109:302-11.
• [25]Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014; 13:465-76.
• [26]Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin Immunol. 2013; 149:279-85.
• [27]Donath MY, Hess C, Palmer E. What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia. 2014; 57:653-5.
• [28]Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006; 2006:59206.
• [29]Uccioli L, Sinistro A, Almerighi C, Ciaprini C, Cavazza A, Giurato L et al.. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care. 2010; 33:350-5.
• [30]Mabilleau G, Petrova N, Edmonds ME, Sabokbar A. Number of circulating CD14-positive cells and the serum levels of TNF-alpha are raised in acute charcot foot. Diabetes Care. 2011; 34: Article ID e33
• [31]Guglielmo-Viret V, Thullier P. Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). J Immunol Methods. 2007; 328:70-8.
• [32]Fu Q, Zhu J, Van Eyk JE. Comparison of multiplex immunoassay platforms. Clin Chem. 2010; 56:314-8.
• [33]Baluk P. Neurogenic inflammation in skin and airways. J Investig Dermatol Symp Proc. 1997; 2:76-81.
• [34]Reikeras O. Immune depression in musculoskeletal trauma. Inflamm Res. 2010; 59:409-14.
• [35]Dimitriou R, Tsiridis E, Carr I, Simpson H, Giannoudis PV. The role of inhibitory molecules in fracture healing. Injury. 2006; 37 Suppl 1:S20-9.
• [36]Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117:3720-32.
• [37]Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes. 2014; 63:1103-14.
• [38]Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol. 2013; 147:242-75.
• [39]Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11:98-107.
• [40]Thomas MV, Puleo DA. Infection, inflammation, and bone regeneration: a paradoxical relationship. J Dent Res. 2011; 90:1052-61.
• [41]Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al.. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13:156-63.
• [42]Sen M, Reifert J, Lauterbach K, Wolf V, Rubin JS, Corr M et al.. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum. 2002; 46:2867-77.
• [43]Caetano-Lopes J, Lopes A, Rodrigues A, Fernandes D, Perpetuo IP, Monjardino T et al.. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. PLoS One. 2011; 6: Article ID e16947
• [44]Hazenberg JG, Hentunen TA, Heino TJ, Kurata K, Lee TC, Taylor D. Microdamage detection and repair in bone: fracture mechanics, histology, cell biology. Technol Health Care. 2009; 17:67-75.